Bronchial lung irrigation solution composition for treating non-small cell lung cancer and preparation method thereof
Patent Information
- Application Number
- CN202511739354.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-11-25
- Publication Date
- 2026-03-10
AI Technical Summary
因此,对肺部菌群的深入研究,特别是发掘能够促进免疫治疗效果的特定微生物,对于开发新的治疗策略具有重要意义,但是,现有技术还无一种有效的微生物组合能临床应用于非小细胞肺癌患者的治疗,因此,基于这一背景,提供一种能通过特定的微生物组合,经病人气道给药的方式(雾化吸入),促进非小细胞肺癌患者免疫治疗效果提升的技术显得非常必要
[0012] Compared with existing technologies, the beneficial effects of this invention are as follows: The composition prepared by this invention delivers these core bacteria directly to the patient's lungs via nebulization or bronchial perfusion, which can in situ increase the level of related beneficial bacteria and, in conjunction with the high immunogenicity of PD-L1/TMB, further enhance the efficacy of PD-1/PD-L1 inhibitors; in vitro cell experiments have verified that microorganisms can promote the production of cytokines such as IL6 and IL8, and further reveal their activation and enhancement effects on immune cell function; since multiple core bacteria coexist, they can simultaneously increase multiple positive immune metabolites through complementary metabolic pathways, synergistically promoting dendritic cell maturation and CD8+ T cell infiltration. The microbial combination can reshape the lung immune microenvironment more comprehensively and continuously than single bacteria, thereby superimposing with the high phenotype of PD-L1/TMB, significantly prolonging the PFS of immunotherapy, demonstrating the amplification effect of "combination is superior to single bacteria", and significantly improving the treatment effect of non-small cell lung cancer.
Smart Images

Figure CN121622746A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of cancer treatment technology, and in particular to a bronchoalveolar lavage fluid composition and preparation method for the treatment of non-small cell lung cancer. Background Technology
[0002] Lung cancer is one of the leading causes of cancer-related deaths worldwide, severely impacting human survival and quality of life. According to the 2020 global cancer statistics released by the International Agency for Research on Cancer (IARC) of the World Health Organization, approximately 2.2 million new cases of lung cancer were diagnosed globally in 2020, with 1.8 million deaths. These figures not only highlight the serious threat lung cancer poses to human health but also underscore the urgency of improving its treatment outcomes. The high incidence and mortality rates of lung cancer place a heavy burden on patients' families and social healthcare systems; therefore, finding more effective treatments has become a focus of global medical research. Non-small cell lung cancer (NSCLC), as the main type of lung cancer, accounts for more than 85% of all lung cancer cases. In recent years, immunotherapy has become the first-line standard of care for driver gene-negative NSCLC. Immunotherapy attacks tumor cells by activating or enhancing the patient's own immune system, providing a new treatment option for NSCLC patients. However, despite significant efficacy in some patients, many still do not respond well to existing immunotherapies. Therefore, improving the effectiveness of immunotherapy is a pressing issue in the current treatment of NSCLC.
[0003] In recent years, significant progress has been made in the study of gut microbiota, particularly its relationship with tumor immunotherapy. Research has revealed that certain gut bacteria can influence the efficacy of immunotherapy by modulating the host's immune response. For example, gut bacteria such as *Bifidobacterium longum*, *Akkermansia muciniphila*, and *Faecalibacterium prausnitzii* have been found to be positively correlated with the efficacy of immunotherapy. These bacteria enhance the host's anti-tumor immune response, thereby improving the effectiveness of immunotherapy. Specifically, *Bifidobacterium longum* can induce dendritic cell (DC) maturation, enhancing the T cell's ability to recognize and kill tumor antigens. *Akkermansia muciniphila* enhances the efficacy of immunotherapy by modulating intestinal barrier function and reducing inflammation. *Faecalibacterium prausnitzii* improves the response rate to immunotherapy by producing short-chain fatty acids (SCFAs) that regulate T cell differentiation and function. These studies provide a scientific basis for enhancing the efficacy of immunotherapy through the modulation of gut microbiota. Although research on gut microbiota has become more in-depth, the clinical efficacy of gut microbiota-enhanced immunotherapy still needs further confirmation through clinical studies.
[0004] Besides the gut microbiota, the lung microbiota, as a microbial community that directly interacts with lung tumor cells, is increasingly attracting attention for its role in immunotherapy for non-small cell lung cancer (NSCLC). Compared to the gut microbiota, the lung microbiota may influence the tumor microenvironment and the efficacy of immunotherapy through a more direct mechanism. Studies have shown that the composition and function of the lung microbiota are closely related to the occurrence and development of lung cancer and its response to treatment. Therefore, in-depth research on the lung microbiota, especially the discovery of specific microorganisms that can promote the efficacy of immunotherapy, is of great significance for developing new treatment strategies. However, current technologies do not yet offer an effective microbial combination that can be clinically applied to the treatment of NSCLC patients. Therefore, against this background, it is essential to provide a technology that can enhance the efficacy of immunotherapy in NSCLC patients through a specific microbial combination administered via the patient's airway (nebulized inhalation). Summary of the Invention
[0005] To overcome the shortcomings of existing technologies, which lack an effective treatment method for non-small cell lung cancer patients based on microbial combinations, this invention provides a bronchoalveolar lavage fluid composition and preparation method that can enhance the immunotherapy effect of non-small cell lung cancer patients through airway administration (nebulized inhalation) via a combination of various beneficial and specific microorganisms.
[0006] The technical solution adopted by this invention to solve its technical problem is:
[0007] A bronchoalveolar lavage fluid composition for the treatment of non-small cell lung cancer (NSCLC) includes s__Segatella_copri, s__Acidilutibacter_cellobiosedens, s__Akkermansia_muciniphila, g_Collinsella, g_Clostridium, s__Anaerostipes_hadrus, and s__Romboutsia_ilealis. The preparation method of the bronchoalveolar lavage fluid composition for the treatment of NSCLC includes the following steps: S1: Metagenomic sequencing of BALF samples from EGFR wild-type NSCLC patients before immunotherapy to obtain 142 differentially expressed bacterial species and 62 differentially expressed bacterial genera. S2: Based on the differentially expressed bacterial species obtained in S1, they were grouped by R / NR, and multiple machine learning algorithms were used for cross-validation and screening to identify the characteristic bacteria that contributed most to PFS prediction, thus obtaining core bacteria. Then, single-bacterial Kaplan-Meier survival analysis was performed on these core bacteria, and finally, seven key microorganisms that were significantly associated with PFS of immunotherapy were identified as biomarkers for predicting the prognosis of immunotherapy using the BALF microbiome. The seven key microorganisms that were significantly associated with PFS of immunotherapy were bronchoalveolar lavage fluid combinations. S3: The relationship between the seven key BALF bacteria and existing biomarkers of immunotherapy efficacy was clarified. S4: In vitro cell experiments were used to verify the role of the seven experimental microorganisms in promoting the production of IL6, IL8, and RANTES cytokines, revealing their activation and enhancement effects on immune cell function.
[0008] Furthermore, in step S1, metagenomic sequencing includes seven sub-steps: sample collection and processing, DNA extraction and quality control, library construction, high-throughput sequencing, data quality control, sequence assembly and annotation, and species and functional analysis.
[0009] Furthermore, in step S1, the sample collection and processing sub-steps must ensure sample representativeness and improve bacterial enrichment through centrifugation / filtration; clinical samples must be handled under strict aseptic conditions and stored at low temperatures. In the DNA extraction and quality control sub-steps, purity, integrity, and concentration must be tested after extraction; low-concentration samples must avoid repeated amplification to prevent introducing bias. In the library construction sub-steps, after DNA fragmentation, libraries are constructed through end repair, adapter ligation, and fragment selection. In the high-throughput sequencing sub-steps, sequencing is performed using the Illumina platform. In the data quality control sub-steps, FastQC is used to assess the quality of raw data, and Trimmomatic is used to remove low-quality reads and adapter sequences. In the sequence assembly and annotation sub-steps, MEGAHIT is used for de novo assembly to generate contigs4, Prodigal is used to predict genes, and functional annotation is performed using databases such as KEGG and GO. The species and functional analysis sub-steps include species identification, diversity analysis, and differential analysis procedures.
[0010] Furthermore, in step S1, during the species identification step of the species and function analysis, relative abundance is calculated by comparing with a reference database; and significantly different species or functional genes are identified by LEfSe.
[0011] Further, in step S3, the relative abundance of core bacteria after log10 transformation is used as a continuous variable, and Pearson two-sided correlation analysis is performed with PD-L1 TPS measured by 22C3-IHC and TMB calculated by whole exon sequencing, with a significance threshold of p < 0.05; the correlation matrix is then formed by the same method and used to evaluate the correlation between BALF community and PD-L1 / TMB.
[0012] Compared with existing technologies, the beneficial effects of this invention are as follows: The composition prepared by this invention delivers these core bacteria directly to the patient's lungs via nebulization or bronchial perfusion, which can in situ increase the level of related beneficial bacteria and, in conjunction with the high immunogenicity of PD-L1 / TMB, further enhance the efficacy of PD-1 / PD-L1 inhibitors; in vitro cell experiments have verified that microorganisms can promote the production of cytokines such as IL6 and IL8, and further reveal their activation and enhancement effects on immune cell function; since multiple core bacteria coexist, they can simultaneously increase multiple positive immune metabolites through complementary metabolic pathways, synergistically promoting dendritic cell maturation and CD8+ T cell infiltration. The microbial combination can reshape the lung immune microenvironment more comprehensively and continuously than single bacteria, thereby superimposing with the high phenotype of PD-L1 / TMB, significantly prolonging the PFS of immunotherapy, demonstrating the amplification effect of "combination is superior to single bacteria", and significantly improving the treatment effect of non-small cell lung cancer. Attached Figure Description
[0013] Figure 1This is a flowchart illustrating the preparation method of the bronchoalveolar lavage fluid composition for the treatment of non-small cell lung cancer according to the present invention.
[0014] Figure 2 , 3 This is a comparison of lung images before and after immunotherapy in non-small cell lung cancer (NSCLC) patients with high levels of respiratory tract enrichment of seven key microorganisms.
[0015] Figure 4 This is a comparison chart showing the enrichment of Segatella copri core bacteria in the respiratory tract of bronchoalveolar lavage fluid composition used in immunotherapy for non-small cell lung cancer, and the longer progression-free survival of non-small cell lung cancer patients before and after immunotherapy.
[0016] Figure 5 This is a comparison chart showing the enrichment of Acidilutibacter cellobiosedens core bacteria in the bronchoalveolar lavage fluid composition used in non-small cell lung cancer immunotherapy, and the longer the progression-free survival of non-small cell lung cancer patients before and after immunotherapy.
[0017] Figure 6 This is a comparison chart showing the enrichment of Akkermansia muciniphila core bacteria in the respiratory tract of bronchoalveolar lavage fluid composition used in immunotherapy for non-small cell lung cancer, and the longer progression-free survival of non-small cell lung cancer patients before and after immunotherapy.
[0018] Figure 7 This is a comparison chart showing the enrichment of Anaerostipes hadrus core bacteria in the respiratory tract of bronchoalveolar lavage fluid composition used in immunotherapy for non-small cell lung cancer, and the longer progression-free survival of non-small cell lung cancer patients before and after immunotherapy.
[0019] Figure 8 This is a comparison chart showing the enrichment of Collinsella core bacteria in the respiratory tract of bronchoalveolar lavage fluid composition used in immunotherapy for non-small cell lung cancer, and the longer progression-free survival of non-small cell lung cancer patients before and after immunotherapy.
[0020] Figure 9 This is a comparison chart showing the accumulation of Clostridium core bacteria in the respiratory tract in bronchoalveolar lavage fluid composition used in immunotherapy for non-small cell lung cancer, and the longer progression-free survival in non-small cell lung cancer patients before and after immunotherapy.
[0021] Figure 10 This is a comparison of the Romboutsia ilealis strain enriched in the respiratory tract and the progression-free survival of non-small cell lung cancer patients before and after immunotherapy, based on bronchoalveolar lavage fluid compositions used in immunotherapy.
[0022] Figure 11 This diagram illustrates the correlation between bronchoalveolar lavage fluid composition used in immunotherapy for non-small cell lung cancer and PDL1 and TMB, as well as PD-L1 expression in non-small cell lung cancer patients when enriched in the respiratory tract.
[0023] Figure 12 This is a schematic diagram illustrating the in vitro experiment of g-Clostridium in a bronchoalveolar lavage fluid composition for immunotherapy of non-small cell lung cancer, and its upregulation of IL-6 secretion.
[0024] Figure 13 This is a schematic diagram illustrating the in vitro experiment of g-Clostridium in a bronchoalveolar lavage fluid composition for immunotherapy of non-small cell lung cancer, and its upregulation of IL-8 secretion.
[0025] Figure 14 This is a schematic diagram illustrating the in vitro experiment of g-Clostridium in a bronchoalveolar lavage fluid composition for immunotherapy of non-small cell lung cancer, and its upregulation of RANTES secretion. Detailed Implementation
[0026] A bronchoalveolar lavage fluid composition for the treatment of non-small cell lung cancer, comprising s__Segatella_copri, s__Acidilutibacter_cellobiosedens, s__Akkermansia_muciniphila, g_Collinsella, g_Clostridium, s__Anaerostipes_hadrus, and s__Romboutsia_ilealis.
[0027] Figure 1As shown, the preparation method of the bronchoalveolar lavage fluid composition for the treatment of non-small cell lung cancer includes the following steps: Step 1: Metagenomic sequencing is performed on BALF (bronchial lavage fluid) samples from EGFR wild-type NSCLC patients (non-small cell lung cancer patients whose epidermal growth factor receptor gene has not undergone specific mutations in tumor cells) before immunotherapy, obtaining 142 differentially expressed bacterial species and 62 differentially expressed bacterial genera. Metagenomic sequencing includes seven sub-steps: sample collection and processing, DNA extraction and quality control, library construction, high-throughput sequencing, data quality control, sequence assembly and annotation, and species and functional analysis. In the sample collection and processing step, it is necessary to ensure sample representativeness and improve bacterial enrichment through centrifugation / filtration. Clinical samples must be handled under strict aseptic conditions and stored at low temperatures. In the DNA extraction and quality control step, purity, integrity, and concentration must be tested after extraction. Low-concentration samples should be avoided from repeated amplification to prevent the introduction of bias. In the library construction step, after DNA fragmentation, the library is constructed through end repair, adapter ligation, and fragment selection. In the high-throughput sequencing step, sequencing is performed using the Illumina platform. In the data quality control step, FastQC is used to assess the quality of raw data, and Trimmomatic is used to remove low-quality reads and adapter sequences. In the sequence assembly and annotation step, MEGAHIT is used to perform de novo assembly to generate contigs4, Prodigal is used to predict genes, and functional annotation is performed using databases such as KEGG and GO. The species and functional analysis step includes species identification and differential analysis. In species identification, relative abundance is calculated by comparing with reference databases (such as Greengenes). In the differential analysis process, LEfSe is used to identify significantly different species or functional genes.
[0028] Figure 1As shown, the second step: Based on the differentially expressed bacteria obtained in S1, patients were grouped into R / NR groups (R / NR grouping is based on the efficacy of immunotherapy, where R group refers to CR (tumor disappearance, no measurable lesions on imaging) / PR (tumor diameter reduction ≥30%), and NR group refers to SD (between PR and PD) / PD (tumor diameter increase ≥20%). Multiple machine learning algorithms were used for cross-validation and screening of characteristic bacteria that contributed most to PFS (progression-free survival) prediction. The core bacteria were obtained, and then single-species Kaplan-Meier survival analysis (a statistical method) was performed on these core bacteria. Ultimately, seven key microorganisms significantly associated with progression-free survival (PFS) in immunotherapy were identified as biomarkers for predicting immunotherapy prognosis using the BALF microbiome. These seven key microorganisms were identified as a combination of bronchoalveolar lavage fluid (BALF) microbiota. The third step was to clarify the relationship between the seven key BALF bacteria and existing immunotherapy efficacy biomarkers. Specifically, the relative abundance of the core bacteria after log10 transformation was used as a continuous variable, and Pearson two-sided correlation analysis was performed with PD-L1 TPS (0–100%) measured by 22C3-IHC and TMB (mut / Mb) calculated by whole-exome sequencing (R 4.2.0), with a significance threshold of p < 0.05. The results were then analyzed using the same method and summarized into a correlation matrix to assess the correlation between the BALF microbiota and PD-L1 / TMB. The fourth step was to verify the role of the seven core bacteria in promoting the production of IL6, IL8, and RANTES cytokines through in vitro cell experiments, revealing their activation and enhancement effects on immune cell function.
[0029] Figure 1 As shown in this embodiment, researchers collected bronchoalveolar lavage fluid samples from a group of newly diagnosed non-small cell lung cancer patients and analyzed the microbial composition of the samples using high-throughput sequencing technology. By combining this with the clinical data of these patients (including PFS, PDL1, etc.), researchers found that the abundance of the above seven bacterial species was significantly higher in patients with better immunotherapy response than in other patients, and a clear improvement in immunotherapy efficacy was observed when these seven bronchoalveolar lavage fluid microorganisms were enriched. Simultaneously, in vitro experiments confirmed that these bacteria can promote the production of cytokines such as IL6, IL8, and RANTES, thereby activating immune function.
[0030] Figure 2 , 3This study compares lung images of non-small cell lung cancer (NSCLC) patients with high levels of respiratory tract enrichment of the seven key microorganisms mentioned in this invention (s__Segatella_copri, s__Acidilutibacter_cellobiosedens, s__Akkermansia_muciniphila, g_Collinsella, g_Clostridium, s__Anaerostipes_hadrus, and s__Romboutsia_ilealis) before and after receiving immunotherapy (such as PD-1 / PD-L1 inhibitors). Figure 4 It is evident that the higher the enrichment level of Segatella copri in the respiratory tract, the more significantly the progression-free survival of non-small cell lung cancer patients after receiving immunotherapy is prolonged. Figure 5 It is evident that the higher the enrichment level of Acidilutibacter cellobiosedens in the respiratory tract, the more significantly the progression-free survival of NSCLC patients after receiving immunotherapy is prolonged. Figure 6 It is evident that the higher the abundance of Akkermansiamuciniphila in the respiratory tract, the more significantly the progression-free survival of NSCLC patients after immunotherapy is prolonged. Figure 7 It is evident that the higher the abundance of Anaerostipes hadrus in the respiratory tract, the longer the progression-free survival of NSCLC patients after immunotherapy tends to be. Figure 8 It is evident that higher abundance of Collinsella in the respiratory tract tends to prolong progression-free survival in NSCLC patients after immunotherapy. Figure 9 It is evident that higher abundance of Clostridium in the respiratory tract significantly prolongs progression-free survival in NSCLC patients after immunotherapy. Figure 10 It is evident that the higher the abundance of Romboutsia ilealis in the respiratory tract, the more significantly the progression-free survival of NSCLC patients after immunotherapy is prolonged. Figure 11 It is evident that NSCLC patients enriched with the bacterial flora of this invention showed significantly increased PD-L1 expression, and the abundance of the bacterial flora was positively correlated with both PD-L1 and TMB, suggesting that the bacterial flora and high immunogenicity characteristics synergistically enhance the response to immunotherapy. Figure 12 As can be seen from the in vitro experiments, stimulation with live g-Clostridium bacteria can significantly upregulate IL-6 secretion, confirming its potential to activate the anti-tumor immune microenvironment. Figure 13 As can be seen from the in vitro experiments, stimulation with live g-Clostridium bacteria can significantly upregulate IL-8 secretion, confirming its potential to activate the anti-tumor immune microenvironment. Figure 14As can be seen from the in vitro experiments, stimulation with live g-Clostridium bacteria can significantly upregulate RANTES secretion, confirming its potential to activate the anti-tumor immune microenvironment.
[0031] Figure 1-14 It can be seen that (1) the abundance of key bacteria such as Segatella copri and Acidilutibacter cellobiosedens in the BALF of immune-benefiting patients is not only positively correlated with high PD-L1 expression and TMB level, but also significantly positively correlated with PFS of immunotherapy. According to this, when treating, the composition can be delivered directly to the lungs by nebulization or bronchial infusion, which can increase the level of related metabolites in situ. In combination with the high immunogenicity of PD-L1 / TMB, it can further enhance the efficacy of PD-1 / PD-L1 inhibitors, providing a new combination therapy strategy for NSCLC based on the regulation of the microbial microenvironment. (2) Since multiple microorganisms can simultaneously increase multiple positive immune metabolites through complementary metabolic pathways, and synergistically promote the maturation of dendritic cells and the infiltration of CD8+ T cells, the combination of microorganisms can reshape the lung immune microenvironment more from multiple angles and continuously than single bacteria. This superimposed with the high PD-L1 / TMB phenotype, it significantly prolongs the PFS of immunotherapy, reflecting the amplification effect of "combination is better than single bacteria". (3) In this invention, PBMCs are stimulated and cultured with specific microorganisms, and the cell supernatant is collected. Flow cytometry is then used for detection; by establishing a standard curve, the concentrations of various key cytokines such as IL-6, TNF-α, IFN-γ, and IL-10 in the supernatant are quantitatively analyzed, thereby efficiently and accurately evaluating the effect of the target microorganism on the function of acquired immune cells.
[0032] Those skilled in the art should understand that although this specification describes embodiments, the embodiments do not necessarily contain only one independent technical solution. This way of describing the specification is only for clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in the embodiments can also be appropriately combined to form other embodiments that can be understood by those skilled in the art. Therefore, the scope of protection of this application is defined by the claims.
Claims
1. Bronchopulmonary lavage fluid composition for the treatment of non-small cell lung cancer, characterized in that, The application discloses a bronchopulmonary lavage fluid composition for non-small cell lung cancer treatment, and a preparation method of the bronchopulmonary lavage fluid composition, and relates to the field of immunotherapy of non-small cell lung cancer. The preparation method comprises the following steps: S1, performing metagenomic sequencing on a BALF sample of an EGFR wild type NSCLC patient before immunotherapy to obtain 142 differential bacterial species and 62 differential bacterial genera; S2, grouping the differential bacterial species obtained in S1 into R / NR groups, cross-validating and screening the characteristic bacteria with the largest contribution to PFS prediction by using multiple machine learning algorithms to obtain core bacteria, and then performing single-bacterium Kaplan-Meier survival analysis on the core bacteria to finally lock seven key microorganisms significantly related to the PFS of immunotherapy as markers for predicting the prognosis of immunotherapy based on the BALF microbiome, namely the bronchopulmonary lavage fluid composition; S3, determining the relationship between the seven key BALF bacteria and existing immunotherapy effect markers; and S4, verifying the promotion of the seven microorganisms on the production of IL6, IL8 and RANTES cytokines through in-vitro cell experiments, and revealing the activation and enhancement of the microorganisms on the function of immune cells.
2. The method of claim 1, wherein the bronchopulmonary lavage fluid composition for the treatment of non-small cell lung cancer is prepared by, In step S1, the metagenomic sequencing comprises seven sub-steps of sample collection and processing, DNA extraction and quality control, library construction, high-throughput sequencing, data quality control, sequence assembly and annotation, and species and function analysis.
3. The method for preparing the bronchoalveolar lavage fluid composition for the treatment of non-small cell lung cancer according to claim 1, characterized in that, In the sample collection and processing sub-step in step S1, the representativeness of the sample needs to be ensured, and centrifugation / filtration is used to improve the bacterial species enrichment degree, and the clinical sample needs to be strictly operated in a sterile manner and stored at low temperature; in the DNA extraction and quality control sub-step, the purity, integrity and concentration of the extracted DNA need to be detected, and low-concentration samples need to be avoided from being repeatedly amplified to prevent bias; in the library construction sub-step, after DNA fragmentation, the library is constructed through end repair, adapter ligation and fragment screening; in the high-throughput sequencing sub-step, the Illumina platform is used for sequencing; in the data quality control sub-step, FastQC is used to evaluate the quality of the original data, and Trimmomatic is used to remove low-quality reads and adapter sequences; in the sequence assembly and annotation sub-step, MEGAHIT is used to perform de novo assembly to generate contigs4, Prodigal is used to predict genes, and KEGG and GO databases are used for functional annotation; and the species and function analysis sub-step comprises the steps of species identification, diversity analysis and differential analysis.
4. The method of claim 1, wherein the bronchopulmonary lavage fluid composition for the treatment of non-small cell lung cancer is prepared by, In the species identification of the species and function analysis sub-step in step S1, the relative abundance is calculated by comparing with a reference database, and LEfSe is used to identify significant differential species or functional genes.
5. The method of claim 1, wherein the composition of the bronchopulmonary lavage fluid for the treatment of non-small cell lung cancer is prepared by, In step S3, the relative abundance of the core bacteria after log10 transformation was used as a continuous variable, and Pearson bilateral correlation analysis was performed on the PD-L1 TPS measured by 22C3-IHC and the TMB calculated by whole exome sequencing, with a significance threshold of p<0.
05. The same method was used for testing and summarizing into a correlation matrix to evaluate the correlation between BALF flora and PD-L1 / TMB.
